The number of drugs picking up a designation from regulators — first treatments or speciality drugs — across the European Union, the US, and Japan have risen by 117 percent in 10 years.
The US states of New Hampshire and South Carolina are suing Purdue Pharma, the manufacturer of OxyContin for its role in the opioid crisis.
Humira has set a record for the highest gross-selling drug in the world and contributed 63 percent to AbbVie’s revenue in 2016 alone and expectations are high the blockbuster drug will continue to perform.
Cancer therapy was historically dominated by chemotherapy and hormonal therapies, but now a new drug class is poised to seize a market share of more than $35bn.
Over the next few years Sanofi will go from being an also-ran in the dermatology arena to being a major player, thanks to the performance of a groundbreaking new drug.
In the lead up to the UK’s departure from the EU, efforts are being made to ensure the stability of the healthcare and pharmaceutical industries.
As divorce talks between the UK and the European Union get underway, the country could soon be deprived of some of its best scientific minds.
Heart surgery, prenatal care, organ transplants, and blood transfusions.
In recent years licensing deals have dominated the pharmaceutical industry.
Biosimilar trials — testing an almost identical copy of a drug originally manufactured by a different company — have exploded in recent years.
Since the UK triggered Article 50 — the formal European Union exit clause — in March the pharma industry has been closely watching where the European Medicines Agency (EMA) is going to relocate.
One of the many issues that needs to be negotiated in the wake of British prime minister Theresa May’s triggering of Article 50 is the location of the European Medicines Agency (EMA).
Depression is the leading cause of disability worldwide, affecting over 300m people – but less than half of them are getting effective treatment.
Drug development is a lengthy, complicated and costly process, with a high rate of attrition.
In developed markets, especially the US, pharmaceutical companies are facing a period of uncertainty, with pricing and reimbursements concerns causing significant barriers to revenue potential.
As the world’s first human head transplant rapidly approaches, it’s time to face the implications this could have for the future of surgery and pharma therapy.
Well-established drug development powerhouses Roche, Celgene, and Novartis are the biggest pharma firms by oncology revenue right now and are set to hold onto the top spots over the next five years.
Times are tough in the healthcare industry and the rise of pharmacoeconomics — when the value of one pharmaceutical drug or drug therapy is compared to another — is not making life any easier for big pharma.
The pharmaceutical industry lies in a cloud of uncertain future policies.
Drug-resistant so-called superbugs kill at least 700,000 worldwide each year and deaths are expected to rise to 10m per year by 2050, according to economist Jim O’Neill.
Over the past few months, there has been a great deal of speculation around what kind of impact Donald Trump‘s presidency will have on healthcare and the pharmaceutical industry.
Given the scarcity of commercially-ready oncology assets, cancer drugs are appealing to big pharma with lots of cash and high prices are being paid for hopeful products.